Evotec International GmbH

SYDNEY, March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024. There will be three presentations in total at AACR, including data from the phase 1 study of EVT801 in advanced solid cancers. The data being presented will outline initial clinical data from the phase 1 study and provides support and direction for the next stage of the study. In addition, data will be presented on the results of the combination therapy of paxalisib and gemcitabine for patients with relapsed/recurrent atypical teratoid/rhabdoid tumors AT/RT. Based on these findings, the Pacific Pediatric Neuro-Oncology Consortium (PNOC) is planning to include this therapy in its next AT/RT international clinical trial. Summary of Abstracts Session PO.CL01.15 - Early Detection Biomarkers 1 April 7, 2024 – 1:30pm-5:00pm Abstract 1059 / 7: Biomarkers analysis on samples from patients in EVT801 clinical trial: Patient characterization and immunomonitoring L. Davenne, M. Fitzgerald, P.-B. Ancey, O. Delpuech, C. Poussereau-Pomié, M. Esquerre, M. R. Paillasse, M. Mandron, P. Rochaix, M. Ayyoub, C. Scarlata, C. Caux, P. Cassier, C. Gomez-Roca, J.-P. Delord, J. Friend, P. Fons Evotec International GmbH, Toulouse, France, Kazia Therapeutics, Sydney, Australia, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France, Centre Léon Bérard, Lyon, France Session PO.CTP01.01 - Phase I Clinical Trials in Progress 1 April 8, 2024 – 9:00am-12:30pm Abstract CT088 / 15: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study C. Gomez-Roca, P. Cassier, M. Fitzgerald, L. Davenne, C. Costantin, P. Rochaix, J.-P. Delord, J. Friend, A. Nizzardo, A. Tagliavini, M. Pergher, P. Fons, M. Mandron Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France, Centre Léon Bérard, Lyon, France, Kazia Therapeutics, Sydney, Australia, Evotec International GmbH, Toulouse, France, Evotec International GmbH, Verona, Italy Session MS.CL08.01 - Novel Approaches for Targeted Therapies April 9, 2024 – 2:50pm-3:05pm Abstract 6565 - Improving survival of atypical teratoid/rhabdoid tumor orthotopic xenografts through the combination of PI3K inhibitor paxalisib and nucleoside analog gemcitabine T. Findlay, K. Malebranche, A. Geethadevi, C. Eberhart, J. Rubens, E. Raabe Johns Hopkins University School of Medicine, Baltimore, MD About Kazia Therapeutics Limited Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, is ongoing, with final data expected in 1H2024. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and FTD for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study is ongoing and preliminary data is anticipated in CY2024. For more information, please visit or follow us on Twitter @KaziaTx. Forward-Looking Statements This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia's clinical and preclinical trials and investigator-initiated trials of Kazia's product candidates, and Kazia's strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on form 20-F with the United States Securities and Exchange Commission (SEC), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. This announcement was authorized for release by Dr John Friend, CEO. Company Codes: NASDAQ-SMALL:KZIA

33 leading international partners, supported by the Innovative Health Initiative (IHI), have teamed up to launch the research consortium iCARE4CVD to better understand cardiovascular disease and optimise future prevention and treatment. By creating one database consisting of data from more than 1 million patients and using artificial intelligence, partners will look for new strategies to shift from a one-size-fits-all approach to personalised care. MAASTRICHT, Netherlands, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The international public-private research consortium iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) has launched to better understand cardiovascular disease and optimise future prevention and treatment. The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk. Cardiovascular disease is very prevalent worldwide with enormous socio-economic impact. It is still the most common cause of death, despite significant advances in therapy. Due to population ageing and unhealthy lifestyle, the number of Europeans suffering from CVD currently exceeds 85 million and is still on the rise. This underscores the critical need for better care pathways to reduce the impact of CVD. “As doctors, we are mostly bound to a one-size-fits-all approach while treating our patients with CVD. Our mission however, within iCARE4CVD, is to personalise diagnosis and management of CVD to improve both outcome and patient satisfaction. We will achieve this by collecting data of more than 1 million subjects in a federated database, analysing them using artificial intelligence (AI) and prospectively validating personalized treatments during the second half of iCARE4CVD,” said Prof Hans-Peter Brunner-La Rocca, coordinator of iCARE4CVD and cardiologist at Maastricht University and Maastricht University Medical Center+ (Maastricht UMC+). To improve patient outcomes, iCARE4CVD aims to improve four aspects of current care: 1) Early diagnosis and classification into clinically meaningful subgroups2) Risk stratification defining urgency for intervention3) Prediction of individual treatment response4) Inclusion of outcomes based on patient perspectives “CVD encompasses a range of intricate, chronic conditions, with atherosclerosis being the most prevalent. Many questions remain about why some individuals with risk factors develop CVD while others do not, and how CVD progresses to more severe stages. iCARE4CVD represents a significant stride towards a deeper comprehension of CVD and the customization of interventions at each stage, catering to individual needs much more effectively,” said Prof Kees Hovingh, Senior Medical Officer and iCARE4CVD Scientific Leader at Novo Nordisk. The voices of people at risk for and those currently living with CVD will be at the heart of iCARE4CVD during the entire project, by using patients’ insights, opinions and wishes. They will help to translate the findings into a more patient-centric and equitable narrative around CVD and its multiple impacts on individuals from both a social and medical perspective. iCARE4CVD will also investigate health outcomes in people with type 1 diabetes at risk of developing CVD, explains Dr Jeanette Soderberg, Director at JDRF. “With the help of such a large European collaboration, we will investigate the impact of novel therapies typically used in type 2 diabetes on clinically important outcomes in the traditionally underappreciated but growing population of type 1 diabetes at risk. With the help of biomarkers, we will also be able to determine who’s in most need for such intervention.” iCARE4CVD has been granted €22 million in funding from the Innovative Health Initiative (IHI) - a joint undertaking of the European Commission and the European life science industry. The project officially kicked off its activities across Europe in October 2023 and will run until 31 March 2028. Project facts Project acronym:iCARE4CVDStart date:01 October 2023Duration:54 monthsBudget: € 22 MioCoordination:University Maastricht, Prof Hans-Peter Brunner-La RoccaProject Lead:Novo Nordisk A/S, Dr Nicholas CicconeWebsite:www.icare4cvd.eu Austria Medizinische Universität WienBelgium Thomas More Kempen VZWDenmark Novo Nordisk A/SFrance Bayer Healthcare SAS FranceFondation Francophone pour la Recherche sur le DiabeteHuawei Technologies FranceINSERM/Mondor Biomedical ResearchGermany Charite - Universitaetsmedizin BerlinEvotec International GmbH Deutsche Stiftung für chonisch KrankeUniversitätsklinikum Aachen WIG2 GmbHIreland University College DublinItaly Fondazione Human Technopole Instituto di ricerche farmacologiche Mario NegriNetherlands Catalyze B.V.Erasmus Universitair Medisch Centrum RotterdamLeids Universitair Medisch CentrumMaastricht University Nederlandse Organisatie voor toegepast natuurwetenschappelijk onderzoek Philips Medical Systems Nederland BVStichting IMEC NederlandUniversitair Medisch Centrum GroningenSwedenAstrazeneca ABSwitzerland Amgen (Europe) GmbHDecentriqRoche Diagnostics International AGSwiss Institute of BioinformaticsUnited KingdomOrbital GlobalThe Queen’s University of BelfastUniversity of GlasgowUnited States Eli Lilly and Company and its AffiliatesJDRF International Funding acknowledgementThis project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio, MedTech Europe and JDRF International. About IHI The Innovative Health Initiative (IHI) is a public-private partnership (PPP) between the European Union and the European life science industries. The partners of IHI are the European Union, represented by the European Commission, and the European life science industry, represented by the industry associations COCIR, EFPIA (including Vaccines Europe), EuropaBio and MedTech Europe. The core goals at IHI, are to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. IHI has a total budget of €2.4 billion and is funded jointly by the EU and by industry associations representing Europe’s life science industries. For further information: www.ihi.europe.eu DisclaimerFunded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them. Further information For questions about this press release or requests for interviews, please contact:Rik van Laake, press officer, Maastricht UMC+0031-621884122rik.van.laake@mumc.nl

当卫材/渤健的阿尔茨海默病新药Lecanemab获FDA全面批准的消息传来，除了对其光辉一幕的赞美，更不能忘记登上这座高山的那群幕后英雄。7月6日，等待数月的好消息终于传来，卫材/渤健联合开发的Lecanemab（以下简称“L药”）用于治疗阿尔茨海默病（AD）的加速批准已成功转为完全批准。二十年来，这是首款获FDA完全批准的阿尔茨海默新疗法。攻克阿尔茨海默病领域这块骨头有多难啃，曾经罗氏的折戟，礼来和卫材的屡次落败，阿斯利康、GSK和BMS曾在这方面的“退却”，足以见得。但败和难，是胜的起点，至少已经有L药在极力证明。站在AD治疗的领域这无疑是一款里程碑式的新药。但在见证历史的时刻，不要忘记了是谁成就了这款药。在L药研发接力赛上，如果错失一个坚持者，或者一个机会，也就不可能有它引领阿尔茨海默病药物走到台前的今天。而不管是L药还是曾经的Aducanumab，从早期研究到成药，到上市，都是众人拾柴的结果。没有Lars Lannfelt，也就没有LecanemabLecanemab的前三个英文字母，来源于Lannfelt-Eisai（卫材）-Collaboration的三个首字母。如果没有这位名叫Lars Lannfelt的内科医生，没有他与瑞典生物化学家 Pär Gellerfors 创立的BioArctic公司，那便没有L药，更不用提如今这振奋人心的一幕。上个世纪80年代初，在瑞士斯德哥尔摩某医院的地下实验室里，Pär Gellerfors第一次见到了Lars Lannfelt。Pär刚从美国做了两年客座研究员回来，并带回了一本《分子克隆:实验室手册》。这本书现在已成为分子生物学的经典著作，但在当时，里面提到的“克隆基因”和“发现突变”等概念，几乎是全新的。虽然常年在医院工作，Lannfelt却对这些一无所知。对此，他感到震撼，也是从那时候开始，他与Pär试图一起绘制间歇性卟啉症(一种遗传性疾病)背后的遗传学和生物化学图谱，并决定深扎实验室，研究罕见早发性疾病。他们探索的开始，为后面合作创立Bioarctic和研发L药的故事，书写了序言。在实验室里一起工作了多年之后，Pär进入制药行业，而Lannfelt开始在卡罗林斯卡医学院的本特·温布莱德实验室工作，该实验室以研究阿尔茨海默病而出名。不久之后，Lannfelt得知在瑞典北部，有许多人在较年轻的时候便患有该疾病。其中一个含11个成员的家庭，他们在平均年龄57岁时便患病。基于在实验室多年对疾病背后突变的钻研，他决定对此展开调查研究。1992年，Lannfelt先是发现了“瑞典突变”，这种突变使淀粉样β蛋白聚集形成聚集体（即斑块），这在患者身上被清楚地观察到，当时瑞典很多一流的科学出版物均刊登了这项发现，但彼时的Lannfelt错失了申请专利的机会。不过，这并不是L药的开端，真正的开始，源自1999年，Lannfel研究小组发现并命名的一种“北极突变”。这种突变导致淀粉样β蛋白错误折叠并呈现出不同的形式，后也会发生聚集。彼时科学家的注意力都在“斑块”这一原因上，但淀粉样蛋白有多种形式，如从微小的可溶蛋白质碎片到患者大脑中杂乱的大斑块。Lannfelt则坚持认为，大脑中可溶性形式淀粉样β蛋白的堆积是真正的病因，Lannfelt团队将其称为“原纤维”。随后，Lannfelt欲对其进行专利申请。不过，由于经验尚缺，Lannfelt花了数月的精力去修改专利申请。所幸在同期，原伙伴Pär离开了HemeBiotech公司，并同样看好Lannfelt发现的靶分子潜力，两者新的伙伴关系正式开始，后找到了专业的专利顾问，解决了申请专利的问题。2001年，“北极突变”这一发现被刊登发表。至此，淀粉样蛋白-β低聚物/原纤维这个治疗阿尔茨海默病的靶点，注定要在史上留名。但起初，推进研究需要钱。21世纪初，IT行业股市的大崩盘波及到生物技术，某段时间里寻求外部资本甚至如天方夜谭。第一批专利发票被塞进Lannfelt和Pär的家庭财务中，由于发票金额太大，只能设法延期付款。“没有人想在我们身上投资一分钱。”Pär曾道出了最初的窘迫，“为了解决问题，我们决定寻找一家可以提供资金帮助的公司。”那时候，Lannfelt和Pär看到了同样在阿尔茨海默领域倾心研究的日本卫材，与其合作之心十分强烈。2003年6月，当在卫材的研究人员面前作出演讲后，Lannfelt和Pär原以为会很久才会收到结果，但谁曾想，就在会面第2天，卫材来电：“您们是否愿意来东京详谈？”也就是在与卫材逐步接洽的那一年，2003年，Lannfelt和Pär共同成了Bioarctic公司，2005与卫材正式开发针对淀粉样蛋白原纤维的抗体。2006年，Pär成为全职CEO，Bioarctic聘请了首批研究人员。一拍即合，“L药”背后的卫材18年2005年，卫材与BioArctic的命运正式交织在了一起。卫材的首席执行官Haruo Naito亦是双方合作中的“关键先生”。他在制药行业工作了几十年，关注阿尔茨海默病的研究时间不亚于BioArctic的两位创始人，并与阿尔茨海默病药物研发做了多年斗争。算起来，卫材从1983年首次进入阿尔茨海默病领域，至今在这条路上已跑了40年。第一次取得突破是于1997年成功开发了Aricept，作为阿尔茨海默病的标准疗法，能够暂时改善认知功能的对症疗法，但其无法从疾病本身成因方面治疗，且可用药期间较短。Haruo Naito并不放弃，曾将为阿尔茨海默病患者提出一种新的治疗方法作为卫材的首要任务。此后多年来，卫材一直致力于研发下一代阿尔茨海默病药物。而BioArctic抛出的橄榄枝迅速吸引了Haruo Naito。“当时BioArctic最吸引我们的便是淀粉样蛋白的发现，特别是原纤维，当时没人知道。”借此，他激动地看到了一种可能性，并由衷感叹“我们可以把这种神奇的药物作为一种治疗阿尔茨海默病的新药物提出来了。”很快，双方一拍即合，BioArctic和卫材在2005年就阿尔茨海默病的疾病修饰治疗进行了研究合作。也是在同一年，BioArctic候选药物mAb158（mAb158是BAN2401/lecanemab的小鼠前体类抗体）在瑞典乌普萨拉大学分离。这只是双方合作的开始。2007年，BioArctic和卫材就抗体BAN2005作为阿尔茨海默病疾病修饰治疗的许可协议签订了许可协议，与此同时提交了关于抗体BAN2401的专利申请；2008年，BioArctic和卫材就BAN2401的后备抗体进行了第二次研究合作；2013年，卫材在美国启动了一项关于候选药物BAN2401的临床2b期研究，并在日本开始了备份临床开发；2014年，BAN2401在阿尔茨海默病中的临床开发在欧洲开始。而卫材和渤健的缘分也始于2014年，双方就BAN2401在阿尔茨海默病中的持续开发和商业化达成协议，这也为三年后加大合作埋下了伏笔。研发仍在紧锣密鼓推进。2015年，BioArctic和卫材加大了合作力度，签订了关于BAN2401备份的许可协议，BAN2401的后续项目，以及关于阿尔茨海默病新疾病修饰疗法的第三项研究合作协议。在卫材的助推下，BAN2401也开始陆续摘得果实。2017年，BAN2401的专利在美国获得授权；2018年，早期阿尔茨海默病的BAN2401 2b期临床研究结果较为优异；2019年BAN2401在早期阿尔茨海默病患者中的3期研究启动，BioArctic与卫材发起了一项进一步研究合作。直到2020年，BAN2401有了一个新名字，被赋予国际非专利名称lecanemab，前三个字母便取自于BioArctic创始人Lannfelt -卫材（Eisai）- Collaboration首字母。更大的进展则来自于2021年，FDA授予L药在阿尔茨海默病中的突破性疗法和快速通道指定。卫材开始向FDA提交申请，以加速途径批准L药在早期阿尔茨海默病中的市场批准。卫材较为丰富的经验助力了L药在后续开发和商业化。Thomas D. Fagan Jr.于2022年7月任命为美国阿尔茨海默病商业化副总裁，负责领导公司阿尔茨海默病业务在美国商业化战略的制定和实施，同时加速团队的成长和扩张。卫材副总裁Alex Scott也是一个关键人物。其父母因患上阿尔茨海默病而离世，他长期关注于阿尔茨海默病药物的研发，并致力于将药物推上市。而今，L药正式上市，成为了20年来首款获得FDA完全批准的阿尔茨海默病新药。不过，关于阿尔茨海默病新药的研发还远未结束。即使淀粉样蛋白的堆积是阿尔茨海默病的第一个迹象，也有其他目标需要解决，比如在患者大脑中堆积的被称为tau的蛋白纠结。而今，卫材已在测试将L药与一种针对tau的药物相结合。A药背后“关键先生”们除了L药，渤健和卫材还合作推出了AD领域的里程碑新药Aducanumab（以下简称“A药”）。尽管该药有争议，但不可否认它曾是自2003年以来FDA批准的首个治疗AD的新疗法，也是首个针对该疾病明确病理机制，减少AD患者大脑中的淀粉样蛋白斑块的治疗方法。A药的研发历程比L药更加曲折，因而涉及的关键人物更多。Roger M. Nitsch、Christoph Hock和Jan Grimm共同创办了Neurimmune Therapeutics，确定了研究思路和技术路线，最终成功筛选出抗体NI-101，这便是A药的“雏形”。在Neurimmune创立初期，最需要资金的时候，Karsten Henco投了500万美元的种子基金。而能将A药推向临床及之后的关键源于一起与渤健的合作，给合作牵线搭桥的是渤健当时的首席医疗官以及主管神经病学研发部门的高级副总裁Alfred Sandrock。在抗体NI-101更早前，还有Dale Schenk对AD免疫治疗的研究，他启动了AN-1792的研究，这一研究是A药的“源头”。故事最早要追溯到1995年。第一个出场的人是Dale Schenk，他当时正在美国加州的Athena Neurosciences公司当神经生物学部的主任。当时AD新药开发的主流方向是寻找抑制淀粉样蛋白产生的化合物。Schenk提出了相反的研究思路：激发患者清除多余淀粉样蛋白的抗体。这个想法一提出便被大家认为不可能，在Schenk的坚持下，被放到了待做试验清单的最后一项——第30项。后来随着该实验的成功，AD免疫治疗的研究时代也开启了。2000年前后，Elan Pharmaceuticals（1996年了收购Athena）启动了AN-1792的临床试验。并在次年9月开始AN-1792的2期临床试验。在此期间，Schenk还因此获得了2001年的Potamkin奖（由美国神经病学学会颁发，授予在脑退行性疾病研究领域中做出卓越贡献的学者）。之后因安全性时间激增，Elan于2002年3月宣布永久暂停AN-1792的临床试验。研发的企业放弃了，但承接AN-1792临床的PI们却坚持了下来。故事的主角也随之变成了Roger M. Nitsch和Christoph Hock，他们两人当时在瑞士苏黎世大学精神科医院分别担任精神病学研究部主任、主任医师，而该医院承接了AN-1792多中心临床的部分。Nitsch和Hock在患者免疫AN-1792一年后又进行了下一步研究，结果显著。2003年Nitsch在神经科学顶级期刊《Neuron》上发表相关文章，重燃起大家对AD抗体的研发热情，Nitsch也因而获得了2004年的Potamkin奖。文章发表后Schenk的团队重返，先进一步明确了免疫AN-1792后产生的靶向Aβ抗体的抗原表位。Nitsch选择了独辟蹊径。并找到当时在美国Rinat Neuroscience当AD研发主管的Jan Grimm帮忙，他在AD的单抗研发方面很有经验，辉瑞后来AD研发管线里的Ponezumab就是在他手下开发出来的。最终他们有了在当时还是“非主流”但成熟的技术实现路线，并且筛选出了初步看着理想的抗体。之后三人在Karsten Henco的建议下，创立了Neurimmune Therapeutics。Henco是EVOTEC BioSystems的创始人，在Neurimmune创立初期提供了种子资金。Nitsch与Henco的缘分在于，之前Nitsch与后者的公司合作注册了一家叫EVOTEC Neurosciences Gmbh的公司，这家公司主要致力于寻找AD的诊治方法，并寻求与制药公司的合作。Nitsch对药物开发有清晰的认识，他认为开发药物并不简单，必须寻找制药公司的合作。而此时A药的关键人物也跟随一个人、一笔交易发生了变化。当时渤健正在为近乎“枯竭”的研发管线而焦急，2004年Biogen Idec为了拓展合作在苏黎世成立了全球总部，地点正好在Nitsch他们所在的小城。天时地利有了，只欠牵线搭桥的人。现今被行业尊称为全球神经科学领域思想领袖的Alfred Sandrock就是这个关键人物，他当时是渤健的首席医疗官以及主管神经病学研发部门的高级副总裁。而他与Nitsch是“老相识”，当时两人都还在学术界，Nitsch在哈佛大学麻省总医院和MIT当博士，而Sandrock在哈佛大学麻省总医院当助理教授。2007年11月，Nitsch和渤健达成最终合作，由Sandrock监督治疗A药的开发。之后的故事便不再赘述。值得关注的是，A药背后的“关键先生”们如今也在自己的征程上继续发光发热。Sandrock在渤健工作了20多年后，去了一家叫Voyager Therapeutics的公司，并被任命为首席执行官。Voyager专注于开发神经系统疾病AAV疗法。而Roger M. Nitsch、Christoph Hock和Jan Grimm三人分别担任Neurimmune公司的CEO、CMO、CSO。登记邮箱信息订阅E药经理人信息服务扫描二维码精彩推荐CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化 ｜ 猎药人系列专题启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖 ｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 |  荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药 ｜再鼎医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元